DBV DBV Technologies S.A.

1.948USD1.776 EUR · EPA+0.23%Mkt Cap: 612.04M USDP/E: —

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…

Institutional holders11 on file

Key Statistics

Company
Market Cap612.04M USD
Enterprise Value438.53M USD
Revenue (TTM)3.74M USD
Gross Profit3.74M USD
Net Income (TTM)-146.95M USD
Revenue/Share0.01 USD
Last Price1.948 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees179
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010417345
Valuation
P/E (Trailing)—
P/E (Forward)-11.92
PEG—
EV/EBITDA-1.94
EV/Revenue117.38
P/S149.36
P/B4.22
EPS (TTM)-0.52 USD
EPS (Forward)-0.15 USD
52W Range
1.6828% of range4.936
52W High4.936 USD
52W Low1.682 USD
Profitability
Gross Margin100.00%
Oper. Margin-5576.98%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.07%
ROA-62.87%
ROIC—
ROCE-83.70%
Growth
Revenue Growth-42.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-121.18M USD
CapEx (TTM)538.00K USD
FCF Margin-3025.12%
FCF Yield-18.47%
Net Debt-158.20M USD
Net Debt/EBITDA0.77
Net Debt/FCF—
Balance Sheet
Debt/Equity0.05
Current Ratio3.24
Quick Ratio3.17
Book Value/Sh0.42 USD
Cash/Share0.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.948 USD
Upside (mean)+102.7%
Target Range0.9871 USD – 6.032 USD
0.9871+102.7% to mean6.032
# Analysts3
Ownership
Shares Out.314.20M
Float207.53M
Insiders0.13%
Institutions57.47%
Technical
SMA 502.070 (-5.9%)
SMA 2003.062 (-36.4%)
Beta-0.21
S&P 52W Chg12.00%
Avg Vol (30d)1.17M
Avg Vol (10d)1.11M
Technical Indicators
RSI (14)45.2
MACD0.0020
MACD Signal0.0049
MACD Hist.-0.0030
BB Upper2.316 USD
BB Middle2.023 USD
BB Lower1.731 USD
BB Width28.93%
ATR (14)0.1304 USD
Vol Ratio (20d)0.67x

About DBV Technologies (EPA: DBV)

›

DBV Technologies (EPA: DBV) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 179 employees.

The shares were at 1.776 EUR on 19 November 2026, down 25.7% over 52 weeks. Its 52-week range is 1.534 EUR to 4.500 EUR: the price is 60.5% below the high and 15.8% above the low.

Its market capitalisation is 558.03M EUR.

DBV Technologies reports return on equity of -87.1% and revenue down 42.9% year over year.

It holds more cash than debt, a net cash position of 158.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 3.600 EUR is 102.7% above the current price. The next earnings report is expected on 25 March 2027.